Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.
Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.
Real-world Patters of Oncology Biosimilars1
Use of biosimilars was found to result in significant cost savings without requiring increased utilization other health care resources, suggesting that they are an ideal alternative to a reference, according to researchers at Intermountain Healthcare and SelectHealth.
Biosimilars offer patients and payers access to lower-cost alternatives to expensive reference products, and more research is needed to show the full financial and clinical impacts of increasing biosimilar utilization.
The researchers collected data on patient claims from SelectHealth, Medicaid, and commercial medial and pharmacy claims for bevacizumab, trastuzumab, and rituximab products between July 1, 2013 and September 21, 2021. In total, 1830 patients had claims for a reference product (Avastin, Herceptin, Rituxan, respectively) and 414 patients had claims for a biosimilar.
Two rituximab biosimilars (Truxima and Ruxience), 3 trastuzumab biosimilars (Ontruzant, Trazimera, and Kanjinti), and 2 bevacizumab biosimilars (Mvasi, Zirabev) were included in the analysis.
Biosimilars for the 3 molecules were found to be statistically significantly cheaper per claim, with cost per claim amounting to approximately $1056 less compared to claims for the reference products. The authors said that this could results in significant cost savings per year for patients and payers.
When claims were divided by the number of patients per product, there were no significant differences observed in supportive care claims between them, suggesting that further investigation into the supportive care space is needed.
Impact of Reclassified Biologic Products on Medicaid Spending2
Although the BPCIA’s follow-on pathways were effective at promoting follow-on competition among long-acting insulins, millions more in savings for Medicaid could have been provided if biologic reclassification was done in 2010 instead of 2020.
Furthermore, if reclassification occurred in 2010, development time, drug patents, and other barriers would likely have delayed competitive biosimilars from entering the market. However, the products may have been able to enter the market before 2021.
The BPCIA is the regulatory work that established the approval pathway for biologics and biosimilars. In 2020, some products, such as insulins, growth hormones, digestive enzymes, that were approved by the FDA using new drug applications were reclassified as biologics as a way to increase competition.
To understand the current level of market competition, the researchers collected data from the Medicaid State Drug Utilization Data between 1991 and 2021 for all reclassified drugs. Afterwards, they estimated the cost of the 10-year preparation period for long-acting insulin products, essentially providing another 10 years of exclusivity for the reference product (Lantus).
The estimated difference in gross reimbursement from 2010 and 2020 was found to be about $4.5 million in missed savings for Medicaid.
The investigators said that the ultimate impact of the BPCIA is still unknown and the introduction of Semglee (insulin glargine), the first biosimilar to receive interchangeability status in the United States, showed promise for additional insulin competition and future interchangeable biologic products.
Semglee entered the market in late 2020 and was automatically priced lower than Lantus and Basaglar. The authors theorized that net costs for insulin glargine could be further reduces as more competitive products like Semglee enter the market.
“Continuing this analysis in 5-10 years will reveal the actual impact of any additional competitors on the reimbursement levels for insulins, growth hormones, enzymes, and other biologic classes,” the investigators said.
Reference
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.